01. Foundational / Icons / 32x32px/Menu @1x Open Menu 01. Foundational / Icons / 32x32px/Close @1x Close Menu
Actor Portrayal

ACIP recommends a 2-dose vaccination series against MMR1,2

Measles outbreaks can still occur within the US.3,4

~1 out of 10 children were unvaccinated against MMR by 24 months of agea,5

aNIS-Child is a random-digit-dialed survey of households that included children aged 19–35 months. Parents or guardians completed a telephone survey and consent to contact the child’s vaccination providers was requested. With parental or guardian consent, identified providers were mailed a questionnaire to obtain vaccination information, which was synthesized to create the child’s comprehensive vaccination history. Children born during 2020–2021 were identified from data collected during 2021–2023, resulting in 28,688 children with adequate provider data for analysis.

Remember to check for children and adolescents who are unvaccinated against measles, mumps, and rubella viruses3,4

The ACIP recommends that children complete a 2-dose vaccine series against MMR viruses.1

M-M-R®II can be used for both doses1

1st Dose

12-15 months of age

2nd Dosea

4-6 years of age

aSecond dose can be administered as early as 4 weeks after the first dose.1

Number of measles cases reported by year3

2010-2024 (as of October 25, 2024)

M-M-R®II catch-up vaccination schedule

For children and adolescents who are unvaccinated against MMR viruses, the CDC recommends catch-up vaccination consisting of a 2-dose series with doses administered at least 4 weeks apart.1

M-M-R®II: Part of the MMRV Family

Discover the MMRV Family

Dosage and administration

Discover the dosing regimen and administration of M-M-R®II.

Review MMR dosing

Clinical data

Explore the robust coverage M-M-R®II offers your pediatric patients.

View MMR Data

References

  1. Centers for Disease Control and Prevention. Recommended child and adolescent immunization schedule for ages 18 years or younger. United States, 2024. Updated June 27, 2024. Accessed October 11, 2024. https://www.cdc.gov/vaccines/hcp/imz-schedules/downloads/child/0-18yrs-child-combined-schedule.pdf
  2. McLean H, Fiebelkorn A, Temte J, Wallace G; Centers for Disease Control and Prevention. Prevention of measles, rubella, congenital rubella syndrome, and mumps, 2013: summary recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(4):1-34.
  3. Measles Cases and Outbreaks. Centers for Disease Control and Prevention. Last Updated October 11, 2024. Accessed October 15, 2024. https://www.cdc.gov/measles/data-research/
  4. Ackerson B, Sy L, Glenn S, et al. Pediatric vaccination during the COVID-19 pandemic. Pediatrics. 2021;148(1):e2020047092. doi:10.1542/peds.2020-047092
  5. Hill HA, Yankey D, Elam-Evans LD, et al. Decline in Vaccination Coverage by Age 24 Months and Vaccination Inequities Among Children Born in 2020 and 2021 — National Immunization Survey-Child, United States, 2021–2023. MMWR Morb Mortal Wkly Rep 2024;73:844–853. DOI: http://dx.doi.org/10.15585/mmwr.mm7338a3

Indications and Usage for M-M-R®II

  • M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II

  • M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.
  • The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and Administration

  • FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

Indications and Usage for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older.
  • The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps

M-M-R®II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age or older. The first dose of M-M-R®II is administered at 12 to 15 months of age and the second dose of M-M-R®II is administered at 4 to 6 years of age.

Selected Safety Information for M-M-R®II (Measles, Mumps, and Rubella Virus Vaccine Live)

  • M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those who are pregnant or are planning to become pregnant within the next month.
  • Due caution should be employed in administration of M-M-R®II to persons with: a history of febrile seizure or family history of febrile seizures; immediate-type hypersensitivity reactions to eggs; thrombocytopenia.
  • Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual’s immune status has been evaluated and the individual has been found to be immunocompetent.
  • Immune globulins (IG) and other blood products should not be given concurrently with M-M-R®II. The ACIP has specific recommendations for intervals between administration of antibody-containing products and live virus vaccines.
  • The following adverse reactions have been identified during both the subcutaneous and intramuscular use of M-M-R®II or its components in clinical trials or reported during post-approval use: fever, rash, and injection-site reactions.
  • The following adverse reactions have been identified during the subcutaneous use of M-M-R®II or its components in clinical trials or reported during post-approval use: headache, dizziness, febrile convulsions, anaphylaxis and anaphylactoid reactions, arthritis, thrombocytopenia, encephalitis and encephalopathy.

Dosage and Administration

  • FOR INTRAMUSCULAR OR SUBCUTANEOUS USE ONLY.
  • M-M-R®II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R®II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

 

Before administering M-M-R®II, please read the accompanying Prescribing Information. The Patient Information also is available.

 

M-M-R®II is contraindicated in certain individuals, including those with: a history of

M-M-R®II is contraindicated in certain individuals, including those with: a history of hypersensitivity to any component of the vaccine, including gelatin; a history of anaphylactic reaction to neomycin; individuals who are immunodeficient or immunosuppressed due to disease or medical therapy; an active febrile illness; active untreated tuberculosis; or those